Holen Sie sich die Stockscreener-App
3.59
0.55%
-0.04
Schlusskurs vom Vortag:
$3.63
Offen:
$3.56
24-Stunden-Volumen:
785.12K
Relative Volume:
0.19
Marktkapitalisierung:
$1.09B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-6.9038
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+0.56%
1M Leistung:
+29.86%
6M Leistung:
-14.45%
1J Leistung:
+51.05%
1-Tages-Spanne:
$3.51
$3.625
1-Wochen-Bereich:
$3.36
$3.835
52-Wochen-Spanne:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.60 | 1.10B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.56 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.77 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
729.95 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.32 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.34 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
AbCellera Biologics Inc. (ABCL) Investor Outlook: Analyzing The 155% Upside Potential - DirectorsTalk Interviews
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Finviz
ABCL Should I Buy - Intellectia AI
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts - TipRanks
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Reports Full Year 2025 Business Results - BioSpace
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
What Sparked AbCellera Biologics To Soar Over 9% After Hours - Bitget
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
AbCellera Biologics Inc. (ABCL) reports Q4 loss, tops revenue estimates - MSN
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
AbCellera Biologics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-02-24 - Seeking Alpha
AbCellera Biologics Q4 Earnings Call Highlights - MarketBeat
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall - ChartMill
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera (ABCL) Achieves Remarkable Revenue Growth in FY25 - GuruFocus
AbCellera Biologics Inc. SEC 10-K Report - TradingView
Abcellera Biologics earnings missed by $0.35, revenue topped estimates - Investing.com South Africa
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - Benzinga
AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan
AbCellera Biologics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Earnings Scheduled For February 24, 2026 - Benzinga
AbCellera Biologics (ABCL) Set to Announce FY Earnings - GuruFocus
AbCellera Biologics FY 2025 earnings preview - MSN
AbCellera Biologics's Earnings Outlook - Benzinga
AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet News
AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com
AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN
Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Investor Outlook: Potential Upside of 205% Amidst Biotech Innovations - DirectorsTalk Interviews
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat
Aug Mood: Is AbCellera Biologics Inc a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3%Still a Buy? - MarketBeat
How resilient is AbCellera Biologics Inc. stock in market downturnsJuly 2025 Weekly Recap & Daily Entry Point Alerts - mfd.ru
State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat
Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):